L2 Asset Management, LLC Biogen Inc. Transaction History

L2 Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 08, 2023	SELL	$253.3 - $285.89 $2.13 Million - $2.41 Million	-8,421 Reduced 98.81%	101 $25,000
Q2 2023 Aug 11, 2023	BUY	$275.25 - $318.06 $2.35 Million - $2.71 Million	8,522 New	8,522 $2.43 Million
Q2 2021 Aug 16, 2021	SELL	$259.0 - $414.71 $1.11 Million - $1.78 Million	-4,294 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$242.95 - $284.63 $480,069 - $562,428	-1,976 Reduced 31.52%	4,294 $1.2 Million
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $722,010 - $1.09 Million	-3,056 Reduced 32.77%	6,270 $1.54 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $17,474 - $20,176	-66 Reduced 0.7%	9,326 $2.65 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $118,983 - $157,573	-460 Reduced 4.67%	9,392 $2.51 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $217,230 - $275,560	-808 Reduced 7.58%	9,852 $3.12 Million
Q4 2019 Feb 13, 2020	BUY	$220.06 - $304.07 $2.35 Million - $3.24 Million	10,660 New	10,660 $3.16 Million

1,032

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.4B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of L2 Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on L2 Asset Management, LLC with notifications on news.